Is Ongentys in shortage in 2026? Get the latest update on Ongentys (Opicapone) availability, cost, and what Parkinson's patients can do right now.
If you rely on Ongentys (Opicapone) to manage your Parkinson's disease symptoms, any hint of a supply problem is alarming. You need your medication — and you need it consistently. So let's cut to the important question: Is Ongentys actually in shortage in 2026?
As of early 2026, Ongentys is not listed on the FDA's official drug shortage database. This means there is no widespread, nationally reported supply disruption for Opicapone. The manufacturer, Neurocrine Biosciences, continues to supply Ongentys to the pharmaceutical distribution network, and it is available through both retail and mail-order pharmacies.
That said, many patients report difficulty finding Ongentys at their local pharmacy. This is a common experience that often gets confused with a true shortage — but the reasons are usually different.
Even without a formal shortage, several factors make Ongentys harder to locate than your typical medication:
Ongentys is a brand-name specialty drug prescribed to a relatively small patient population. Large chain pharmacies prioritize shelf space for high-demand medications. If your local CVS or Walgreens doesn't have regular Ongentys customers, they likely don't keep it in stock. This doesn't mean it's unavailable — it just needs to be ordered.
There is currently no generic version of Opicapone. The earliest a generic could appear is after the patent expiration in March 2030. Without a generic option, there's only one manufacturer producing this drug, which means the entire supply depends on a single source.
Prior authorization requirements and step therapy policies can create delays that feel like supply problems. If your insurance requires you to try Entacapone first, or if your prior authorization lapses, you may find yourself temporarily unable to fill your prescription — not because of a shortage, but because of paperwork.
With a retail price of $645 to over $1,000 per month, Ongentys is an expensive medication. The high cost means fewer patients take it (compared to generic alternatives), which in turn means pharmacies are less likely to stock it proactively. For ways to reduce your costs, see our guide on how to save money on Ongentys.
Here's a snapshot of what you can expect to pay for a 30-day supply (30 capsules) of Ongentys 50 mg:
The Ongentys Savings Program from Neurocrine Biosciences is the best deal for commercially insured patients, potentially reducing your out-of-pocket cost to just $25 per prescription. Learn more at ongentys.com/support.
While there's no generic Ongentys yet, here's what's happening in the Parkinson's treatment landscape that may affect your options:
If your pharmacy doesn't have Ongentys, here's your action plan:
For detailed tips on each of these strategies, read our full guide on how to find Ongentys in stock near you.
The bottom line: Ongentys is not in a national shortage in 2026, but it can still be hard to find at your local pharmacy due to low stocking, high cost, and insurance barriers. The most reliable ways to get it are through mail-order pharmacy, the Ongentys Savings Program, and tools like Medfinder.
If you're experiencing persistent difficulty accessing Ongentys, talk to your neurologist about your options. There are effective alternatives available, and your doctor can help you decide whether switching makes sense or whether a different access strategy is the better path forward. For more information, check out what Ongentys is and Ongentys drug interactions.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
